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Polymorphism of drugs has been the subject of intense interest in the
pharmaceutical industry for over forty years. Although identical in chemical
composition, polymorphs differ in bioavailability, solubility, dissolution rate,
chemical and physical stability, melting point, colour, filterability, density, flow
properties, and many other properties. The difference in solubility is particularly
important for pharmaceuticals, as it can affect drug efficacy, bioavailability and
safety. Despite significant investment in processes to find all the possible
polymorphs of active pharmaceutical ingredients (APIs), new polymorphs can
suddenly appear without warning. Polymorphs tend to convert spontaneously
from less stable to more stable forms, and, therefore, it is best to discover and
characterize the stable form as early as possible. Ideally the most stable
polymorph will be found while the drug candidate is still in the discovery
process, so that this is the form used for subsequent testing. The most stable
polymorph will be the least soluble and solubility may be a limiting factor in the
efficacy of the API. Despite the huge importance of polymorphism in the
properties of materials, however, there is no method that can produce all the
stable polymorphs of a compound, or even one that can provide confidence that
the most stable polymorph has been obtained. Here we describe a new method,
‘potentiometric cycling for polymorph creation (PC)2’, which is able to generate
the most stable polymorph in aqueous solution. This new method has been
applied to sulindac, a non-steroidal anti-inflammatory drug, which also shows
promise in anticancer treatment, producing two polymorphs of this API,
including a new more stable one. By adjusting the conditions, this method is able
to produce either polymorph exclusively.
1. Introduction
A new method, ‘potentiometric cycling for polymorph creation
(PC)2’, to generate multiple polymorphs in aqueous solution is
described. In a study of the solubility of sulindac, two different
polymorphs, characterized by powder X-ray crystallography, were
found to have similar packing motifs, similar calculated energies but
distinct structures. Despite the similarity of the structures, the
intrinsic solubilities of the polymorphs differ by a factor of seven,
which is much larger than earlier measurements of polymorph solu-
bilities, and suggests that polymorphs may have a much greater
solubility range than most precedent suggests. By adjusting the
conditions, the method is able to produce either polymorph exclu-
sively.
Polymorphism of drugs has been the subject of intense interest in
the pharmaceutical industry for over 40 years. Although identical in
chemical composition, polymorphs differ in bioavailability, solubility,
dissolution rate, chemical and physical stability, melting point, colour,
filterability, density and flow properties, amongst other things. The
difference in solubility can affect drug efficacy, bioavailability and
safety. Despite significant investment to find all the possible poly-
morphs of active pharmaceutical ingredients (APIs), new polymorphs
can suddenly appear without warning. Polymorphs tend to convert
from less stable to more stable forms. Therefore, it is best to work
with the most stable polymorph, even though this will be the least
soluble.
When polymorphic conversion occurs it may be impossible to
reproduce the less stable form. Abbott lost a quarter of a billion
dollars in a year when a new polymorph of Ritonavir, an AIDS drug,
appeared in their production lines, first at a production plant in North
Chicago and then at a plant in Italy (Rouhi, 2003). Despite their
efforts to stop the new form appearing, in a few days the new poly-
morph was dominating the product coming off the lines. This new
polymorph was thermodynamically more stable than the old one and
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had half of the solubility. Ritonavir was taken from the market and
millions were spent trying to obtain the first form again. The company
finally reformulated the drug in the second polymorphic form as a
liquid gel capsule that required refrigeration. Similar cases have been
reported (Rouhi, 2003; Goho, 2004). New forms may appear as a
result of a change in the equipment used to dry the final drug
substance, whilst materials are being stored and even with no
recorded change in the storage conditions. The appearance of a new
polymorphic form of an API is a major concern for pharmaceutical
companies.
A new method to generate polymorphs in aqueous solution has
been discovered, using a development of a potentiometric acid–base
titration described by Stuart & Box (2005) and developed commer-
cially by Sirius. The titration method was designed to measure the
intrinsic solubility of ionizable compounds and to ensure that ther-
modynamic equilibrium is reached in a short time.
When an ionizable compound dissolves in water, the pH of the
solution shifts. Small changes in the pH of the solution may change a
supersaturated solution into a subsaturated one. Careful control of
the pH of the solution by addition of acid and base, and precise
monitoring of the resultant pH, allow the equipment to determine if
the changes in the pH of the solution are due to more compound
dissolving, indicating a subsaturated solution, or due to the
compound precipitating, indicating a supersaturated solution.
Repeated cycling between these two states is possible by tiny
adjustments to the pH of the solution by addition of acid and base.
Each change makes the solution cross the precise concentration of
saturation, and many measurements of this state may be made in a
short time. This process is called ‘chasing equilibrium’ (Stuart & Box,
2005) and allows the rapid measurement of the thermodynamic
intrinsic solubility of the solute.
We have applied this process to measure the aqueous solubility of
sulindac, a non-steroidal anti-inflammatory drug, which also shows
promise as an anticancer treatment (Giardello et al., 1993). At first,
the experiment produced measurements following the usual pattern,
and the readings converged on an intrinsic solubility of 70 mg ml1.
short communications
380 Antonio Llina`s et al.  Reproducible generation of polymorphs J. Appl. Cryst. (2007). 40, 379–381
Figure 1
Molecular configurations of sulindac: (a) Form I and (b) Form II. C atoms are
shown in grey, H atoms in white, O atoms in red, fluorine in yellow and sulfur in
green.
Figure 2
Crystal packing of both polymorphs of sulindac: (a) Form I and (b) Form II.
However, after about 20 min, there was a dramatic change in the
measurements, and the readings jumped from oscillating around
70 mg ml1 to oscillating around 10 mg ml1. This experiment was
repeatable, and it was possible to create one form of solid sulindac
(Form I) by stopping the experiment before the 20 min transition,
and to create a sample of the other form (Form II) by running the
experiment for a longer time. Raman spectroscopy was used to follow
the transformation in situ. This technique demonstrated that two
different solid materials were being formed, but could not give
detailed information about their structures.
The two solid forms could be different hydrates, or different salts
of sulindac. We characterized them using differential scanning
calorimetry (DSC), thermogravimetric analysis (TGA), infrared
spectroscopy (IR), Raman spectroscopy, and X-ray crystallography.
Powder X-ray patterns were obtained for both forms. The powder
pattern for Form I matched a pattern reported in the Cambridge
Structural Database (CSD; Bruno et al., 2002) (refcode DOHREX;
Koo et al., 1985). We were able to obtain a crystal of this substance,
and a further X-ray experiment confirmed that it corresponded to this
previously reported crystal structure of sulindac.
The powder X-ray pattern for the less soluble structure, Form II,
does not correspond to anything in the CSD.1 The DSC and TGA
measurements confirmed that, like Form I, it had no solvent in the
crystal structure, and so it was not simply a different hydrate of
sulindac. We were unable to grow crystals of this form that were
suitable for single-crystal X-ray crystallography, but we were fortu-
nate that it was possible to solve the crystal structure of Form II from
the powder X-ray diffraction pattern, using the simulated annealing
algorithm implemented in DASH (David et al., 1998). The model
suggested by DASH was then refined against the data using the
Rietveld method as implemented in the GSAS (Larson & Von
Dreele, 2000) program suite. This gave a fully acceptable final fit and
structural model, with 2 = 2.792, Rwp = 0.0505 and Rp = 0.0381. RBragg
was 0.0749. Final lattice parameters in the P21/c setting were a =
12.6858 (3), b = 8.1894 (2), c = 17.7934 (5) A˚,  = 106.011 (3), V =
1776.83 (6) A˚3.
Fig. 1 shows the conformation of the individual sulindac molecules
in the two crystal structures. The molecules are drawn so that the
planar fused six- and five-membered rings are in the same orientation
for both, illustrating how the relative positions of the acid group at
one end and the sulfoxide at the other differ. Fig. 2 shows the crystal
packing of the two forms.
In common with previous studies (Threlfall, 2003) the new
polymorph of sulindac is less soluble than the original one. The
factor of seven between the intrinsic solubilities is unusually large.
A recent survey of polymorph pairs showed few ratios larger than
two (Pudipeddi & Serajuddin, 2005). Our result suggests that poly-
morphs may have much more diverse solubility than is usually
considered.
In conclusion, this new approach, provides a reproducible method
of preparing two different polymorphs of an API. The new poly-
morph, characterized using Raman spectroscopy, IR, DSC, TGA and
powder diffraction, shows a substantially lower solubility than the
original polymorph, and this could have a significant impact on the
manufacture and the formulation of this material.
2. Experimental section
Solubility measurements. The apparatus used to perform the solubi-
lity determinations was a GLpKa titrator and a D-PAS spectrometer
controlled from a computer running Refinement Pro and CheqSol
software (Sirius Analytical Instruments Ltd). All experiments were
performed in 0.15M KCl solution under nitrogen atmosphere, at
298.2 (1) K, using standardized 0.5M HCl and 0.5M KOH solutions.
Differential scanning calorimetry. Differential scanning calorimetry
was performed on powdered samples using a Metler Toledo DSC
821e, with Metler Toledo STARe software. Around 5–10 mg of each
sample was run in a sealed aluminium pan with a hole pierced in the
lid. Each run was carried out under nitrogen purge at a heating rate of
283 K min1.
Thermogravimetric analysis. Thermogravimetric analysis (TGA)
was carried out on powdered samples (5–10 mg) using a Metler MT5
balance. Data were processed using Metler Toledo STARe software.
Powder X-ray diffraction. X-ray powder diffraction was performed
using Co K1 radiation ( = 1.79 A˚) on a Stoe Stadi-P diffractometer
operating in Debye–Scherrer geometry. The sample was contained in
a 0.7 mm-diameter borosilicate capillary (Lindemann glass). Data
sets with relatively high signal–noise ratios suitable for structure
solution were collected at 290 K (approximate counting time 24 h per
data set). For the Rietveld refinement, suitable constraints on bond
lengths, angles and planar groupings were employed, which were
taken from the single-crystal study. These constraints were applied to
all atoms, including H atoms, which were included at calculated
distances and allowed to refine. A single ADP was employed.
Single-crystal X-ray diffraction. Single crystals were immersed in
perfluoropolyether oil, mounted on thin glass fibres and placed in a
low-temperature N2 stream. Crystals were examined on a Nonius
KappaCCD diffractometer using thin-slice  and ! scans at 150 (2) K
utilizing Mo K radiation. Low temperatures were achieved using an
Oxford Instruments Cryostream cooler. Data for this sample were
corrected for absorption anomalies using the SORTAV utility.
Structures were solved by direct methods using SHELXTL software.
Refinements were made on F 2 with all non-H atoms refined aniso-
tropically and H atoms were treated using a riding model (Sheldrick,
1998). The data have been deposited in the CSD.
Raman spectroscopy. A Raman RXN1 analyser from Kaiser
Optical Systems Inc. was used to monitor the experiments in real
time.
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1 The CIF file for sulindac Form II can be obtained free of charge from the
Cambridge Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/cgi-
bin/catreq.cgi (code CCDC 637252). Supplementary data for this paper are
also available from the IUCr electronic archives (Reference: KK5012).
Services for accessing these data are described at the back of the journal.
